Inhibition of α-synuclein Cell-cell Transmission by NMDAR Blocker, Memantine
NCT03858270
·
clinicaltrials.gov ↗
PHASE3
Phase
UNKNOWN
Status
50
Enrollment
OTHER
Sponsor class
Conditions
Parkinson Disease
Interventions
DRUG:
Memantine
OTHER:
Placebo
Sponsor
Wayne State University